Table 1. Baseline characteristics of the total population.

Patient number	Sex	Age	Histology	Stage at diagnosis	PIK3CA mutation	Sirolimus CTx (line)	Best Response	PFS (weeks)	Comments
1	F	54	Breast	I	H1047R	10	PD	1.87
2	F	72	Sarcoma	IV	R818H	5	SD	2.53
3	F	58	Colorectal	IV	H1047R	6	PD	1.27
4	F	45	Gallbladder	IV	Q546K	3	PD	1.83
5	M	73	Cholangiocarcinoma	IV	E453K	3	NA	1.80	Expired prior to disease evaluation
6	F	57	MUO	Unknown	E545K	9	PD	2.67
7	M	37	Lung	IV	G545L	4	PD	0.60
8	F	42	GBM	Unknown	R38S	4	SD	5.03	Ongoing
9	F	57	Ovarian	IV	E493X	10	NA	0.97	Non-target lesion
10	M	57	Stomach	IV	E453K	5	PD	2.00
11	F	56	Colorectal	IV	E542K	5	PD	2.23
12	F	48	Colorectal	IV	H1047R	4	PD	1.97
13	M	61	Lung	IV	Amp	4	NA	1.10	Expired prior to disease evaluation
14	F	68	Sarcoma	IV	E545K	3	SD	3.87
15	F	59	Colorectal	IV	E365K	4	PD	1.73
16	F	57	Breast	III	Amp	3	SD	3.93
17	M	65	Sarcoma	IV	Amp	5	PD	1.90
18	F	45	Colorectal	IV	E545K	4	PD	2.27
19	F	36	Ovarian	IV	E542K	6	NA	0.70	Withdrawal
20	M	40	Colorectal	III	E545K	7	PD	2.40
21	M	53	Adrenal cortical	IV	G545A	3	PD	2.53
22	M	62	Colorectal	IV	G106V	5	PD	2.23
23	F	50	Sarcoma	IV	PTEN loss	13	SD	8.83	Ongoing
24	F	55	Ovarian	IV	H1047R	8	SD	2.80

CTx, chemotherapy; MUO, malignancy of unknown origin; GBM, glioblastoma multiforme; amp, amplification.